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Background: The objective of the Scandinavian Society of Anaes-
thesiology and Intensive Care Medicine (SSAI) task force on fluid
and drug therapy in adults with acute respiratory distress syn-
drome (ARDS) was to provide clinically relevant, evidence-based
treatment recommendations according to standards for trustworthy
guidelines.
Methods: The guideline was developed according to standards
for trustworthy guidelines, including a systematic review of the
literature and use of the GRADE methodology for assessment of
the quality of evidence and for moving from evidence to recom-
mendations.
Results: A total of seven ARDS interventions were assessed. We
suggest fluid restriction in patients with ARDS (weak recommen-
dation, moderate quality evidence). Also, we suggest early use of
neuromuscular blocking agents (NMBAs) in patients with severe
ARDS (weak recommendation, moderate quality evidence). We
recommend against the routine use of other drugs, including corti-
costeroids, beta2 agonists, statins, and inhaled nitric oxide (iNO)
or prostanoids in adults with ARDS (strong recommendations:
low- to high-quality evidence). These recommendations do not
preclude the use of any drug or combination of drugs targeting
underlying or co-existing disorders.
Conclusion: This guideline emphasizes the paucity of evidence
of benefit – and potential for harm – of common interventions in
adults with ARDS and highlights the need for prudence when
considering use of non-licensed interventions in this patient pop-
ulation.
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Editorial comment: what this article tells us
Current fluid and drug therapy recommendations for patients with ARDS are presented, together
with a critical review of the evidence. These guidelines are sponsored by the Clinical Practice
Committee of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine (SSAI).
The SSAI also owns this journal.
An electronic version of this guideline can be accessed at www.ssai.info/guidelines/
Following its identification by Ashbaugh in
1967,1 the acute respiratory distress syndrome
(ARDS) was first defined by an American-
European Consensus Conference (AECC) in
1994.2 The original definition was recently
revised and is now known as the Berlin
definition.3 Briefly, ARDS is defined as
hypoxemic respiratory failure, classified as
mild (26.6 kPa < PaO2/FIO2 ≤ 40 kPa), moderate
(13.3 kPa < PaO2/FIO2 ≤ 26.6 kPa), and severe
(PaO2/FIO2 ≤ 13.3 kPa) (Table 1).
The underlying pathophysiology of ARDS is
an evolving concept that involves the inflamma-
tory cascade, fluid dynamics, lung mechanics and
the pulmonary circulation.4 Recently both phe-
notypic and genotypic categorization have added
to our understanding of ARDS.5,6 However, apart
from lung mechanics, the manner in which our
pathophysiological insight will ultimately influ-
ence therapy in ARDS remains unclear.
Numerous clinical trials have addressed
whether different fluid and drug regimens may
improve the clinical outcome of ARDS in gen-
eral.7 In the present guideline, we systemati-
cally and transparently review the available
evidence for fluid and drug interventions in
patients fulfilling the ARDS criteria regardless
of the underlying disease.
The Clinical Practice Committee of the Scandi-
navian Society of Anaesthesia and Intensive
Care Medicine (SSAI) initiated this work. The
aim was to summarize the available evidence
and provide recommendations according to new
standards for trustworthy guidelines, as out-
lined by the Institute of Medicine (IOM), the
Guideline International Network (GIN), and
according to the GRADE methodology.8–10
Other authoritative sources such as UpToDate
and the Surviving Sepsis Campaign have also
applied GRADE in their guidelines for the adju-
vant use of fluids and drugs in adults in
ARDS.11,12
Methods
Process
Members of the guideline task force were
selected by the national societies of anaesthe-
siology in Denmark, Finland, Iceland, Norway,
and Sweden, following invitation from the Clin-
ical Practice Committee of the SSAI. We fol-
lowed the standards for trustworthy guidelines,
including the use of the GRADE system, man-
agement of intellectual and financial conflicts of
interest on a recommendation per recommen-
dation basis (see Appendix B), a peer review
process, and a plan for updating of recommen-
dations. We did not include patient representa-
tives in the guideline process.
GRADE
As recently recommended for intensive care
medicine,13 we used the Grading of Recommen-
dations Assessment, Development and Evalua-
tion (GRADE) system for formulating clinical
Table 1 The Berlin definition of the acute respiratory distress
syndrome (ARDS)3:
ARDS is characterized by the following four criteria:
1 Lung injury of acute onset, within 1 week of an apparent
clinical insult and with progression of respiratory symptoms
2 Bilateral opacities on chest imaging not explained by other
pulmonary pathology (e.g. pleural effusions, lung collapse,
or nodules)
3 Respiratory failure not explained by heart failure or volume
overload
4 Decreased arterial PO2/FiO2 ratio:
 mild ARDS: ratio is 201–300 mmHg (≤ 39.9 kPa)
 moderate ARDS: 101–200 mmHg (≤ 26.6 kPa)
 severe ARDS: ≤ 100 mmHg (≤ 13.3 kPa)
A minimum PEEP of 5 cmH2O is required; it may be delivered
non-invasively with CPAP to diagnose mild ARDS.
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questions, assessing the quality of evidence,
generating anticipated absolute effects, and
moving from evidence to recommendations.
Briefly, clinical questions were formulated in
the so-called PICO format,14 which identify the
relevant patient population and/or clinical prob-
lem (P), the intervention (I) under scrutiny as
well as the comparator (C), and patient-impor-
tant outcomes (O) (Table 2).
For literature review, we first searched the
McMaster PLUS database to identify high-qual-
ity systematic reviews of randomized trials. If
more than one relevant systematic review was
identified, we chose the most recent one(s)
with highest methodological quality (lowest
risk of bias). We excluded studies with obser-
vational design and physiological studies based
on our assumption that these would not pro-
vide us with higher quality evidence than what
we would identify from available randomized
trials. If no recent high-quality systematic
reviews were found, we searched the following
databases: PubMed, Embase, Google Scholar,
and the Cochrane Library (Appendix A). When
available, published systematic reviews were
used to identify relative effect estimates and
assess the quality of evidence for the prede-
fined patient-important outcomes. If we identi-
fied additional relevant trials not included in
existing systematic reviews, we updated the
meta-analyses with data from the identified
RCTs. We generally used Mantel–Haenszel
statistics and random effects models in the
meta-analyses (Review Manager Version 5.3.
Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014). In addition, we
used trial sequential analysis to assess the
potential for random errors (sparse data with
spurious findings).15,16 Our review was com-
pleted in June 2015.
Table 2 Clinical problems and PICO questions used to assess evidence relevant to this guideline statement.
Informal clinical question
PICO Question
Population (P) Intervention (I) Comparator (C) Outcomes (O)
1. Should liberal or restrictive
fluid therapy be used in
patients with ARDS?
Mechanically ventilated adults
with acute respiratory
distress syndrome (ARDS)
Liberal fluid therapy Restrictive fluid
therapy
Mortality
28/30 days
60–180 days
-ICU
-Hospital
-Hospital
2. Should corticosteroids be
used in patients with ARDS?
Corticosteroids at any dose
or duration and route
of administration
Placebo or none Oxygenation efficiency
3. Should beta2 agonists be used
in patients with ARDS?
Beta2 agonists at any dose
or duration and route
of administration
Placebo or none Ventilator-free days
4. Should neuromuscular blocking
agents (NMBAs) be used in
patients with ARDS?
NMBAs at any dose
or duration
Placebo or none Days of mechanical
ventilation
5. Should inhaled nitric oxide
be used in patients with ARDS?
Inhaled nitric oxide at
any dose or duration
Placebo or none LOS in ICU
6. Should prostanoids be used in
patients with ARDS?
Prostanoids at any dose or
duration and route
of administration
Placebo or none Use of rescue
therapies
7. Should statins be used in
patients with ARDS?
Statins at any dose or duration Placebo or none Other organ failure
8. Should any other drugs be
used in patients with ARDS?
Any other drug at any dose
or duration and route
of administration
Placebo or none Barotrauma
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We provide GRADE evidence profiles and
Forest plots of meta-analyses in Appendix A. In
keeping with the GRADE methodology, the
quality of evidence for an intervention (i.e. our
confidence in the effect estimates) was rated
down for identified risks of bias (e.g. due to
lack of blinding or early termination of studies),
inconsistency (i.e. unexplained heterogeneity),
indirectness (e.g. different patient populations
or use of surrogate outcomes), and imprecision
(wide confidence interval around the effect esti-
mate).17 Importantly, however, when the out-
come in question was death at any stage, we
did not downgrade evidence due to lack of
blinded outcome assessment. Accordingly, the
quality of evidence was rated from ‘high’ to
‘very low’.
We generated absolute effect estimates by
applying baseline risk estimates to the relative
effect estimates from the meta-analyses. Baseline
risk estimates were taken from the control arms
of randomized trials in the systematic reviews –
in the absence of available high-quality obser-
vational data. Recommendations were based on
the predefined PICO questions.
When moving from evidence to recommenda-
tions, four factors were considered and inte-
grated: Benefits and harms, quality of evidence,
values and preferences (of patients or their prox-
ies), and cost considerations. GRADE classifies
recommendations as strong when virtually all
informed patients would choose the recom-
mended management strategy. Weak recommen-
dations, which reflect a close call between
benefits and harms, uncertainty regarding treat-
ment effects, questionable cost-effectiveness, or
variability in values and preferences, apply
when fully informed patients would choose dif-
ferent management strategies.10,18
The group agreed upon the recommendations
in this document. Strong recommendations were
given the wording ‘we recommend’ and weak
recommendations ‘we suggest’.
Results
A general note on recommendations for
unlicensed drug use
No drug or fluid regimen has been licensed for
use in ARDS, a condition that is relatively rare
and highly lethal, and clearly outside the pri-
mary sphere of interest for pharmaceutical com-
panies. Our task has been to investigate if there
is evidence from empirical research that never-
theless supports the use of specific fluid regi-
mens or drugs in adults with ARDS. We believe
that any recommendation for the use of an inter-
vention must be based on evidence from clinical
trials that demonstrate clear net benefit with
respect to patient-important clinically relevant
outcomes in the population of interest. In the
absence of such evidence, we must consider the
risks: all interventions must be expected to carry
a risk of side effects that may or may not be
related to the condition that we seek to cure.
Absence of proof of benefit should caution the
clinician to consider the – often unknown and
sometimes severe – risks that patients are sub-
ject to when interventions are used outside of
their license and without any documentary sup-
port. We reason that we must recommend
against the use of interventions in such cases.
Table 3 gives recommendations and key infor-
mation, including briefly outlining benefits and
harms, quality of evidence, values preferences,
and cost considerations. Recommendations are
mainly based on the absolute risk of death,
being the most critical patient-important out-
come. Death at some pre-specified time point
following inclusion is also the primary outcome
measure of the included studies. Follow-up time
is variable, however, ranging from 28–30 days
to 180 days (or ICU and hospital mortality).
Interpretation and use of other patient-impor-
tant outcomes were difficult as they were incon-
sistently and diversely reported across trials and
in the systematic reviews.
Recommendation 1: Fluid therapy
(Appendix S1; Table S1, Fig S1)
We suggest fluid restriction over a liberal fluid
strategy in adults with ARDS (weak recommen-
dation, moderate quality evidence). The physio-
logical rationale for limiting fluid volume in
ARDS has been detailed in numerous reviews
and is supported by clinical evidence.19–21 Our
recommendation is based on the results from
the ARDS network trial (FACTT study)19 that
compared a fluid-restrictive vs. fluid-liberal
approach in adults with mild to severe ARDS
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(i.e. targeting either a neutral fluid balance or
central venous pressure and pulmonary–artery–
occlusion pressure at 10–14 mmHg and 14–
18 mmHg, respectively). The quality of evidence
was downgraded for indirectness because the
only major effect on outcomes was a reduction
in time on mechanical ventilation with no sig-
nificant effect on mortality or other organ fail-
ure. Of note, in a post hoc analysis it was found
that enrolment in the conservative fluid-man-
agement strategy was associated with cognitive
impairment.22 Additional evaluation of this out-
come in future research projects seem appropri-
ate and may impact on recommendations if
confirmed by higher quality evidence.
Recommendation 2: Corticosteroids
(Appendix A; Table S2, Fig S2)
We recommend against the routine use of corti-
costeroids in any dose or duration in adults
with ARDS (strong recommendation, low-qual-
ity of evidence). This does not preclude the use
of corticosteroids targeting any underlying con-
dition or co-existing disease in which steroids
are indicated (e.g. auto-immune disease). Our
recommendation is based on the systematic
review by Ruan and et al.23 that aggregated data
from eight randomized trials and a total of 725
patients24–31 and found no difference between
patients receiving steroids vs. patients not
receiving steroids. The quality of evidence was
downgraded due to significant unexplained
heterogeneity between trials and imprecision
around the effect estimate (risk ratio for death,
0.91; 95% CI 0.71–1.18). (See Footnote* )
Recommendation 3: Beta2 agonists
(Appendix A; Table S3, Fig S3)
We recommend against the routine use of beta2
agonists in adults with ARDS (strong recommen-
dation, low-quality of evidence). This does not
preclude the use of beta2 agonists in patients
with an underlying condition or co-existing dis-
ease in which beta2 agonists are indicated [e.g.
asthma or chronic obstructive pulmonary disease
(COPD)]. Our recommendation is based on a
recent systematic review of three randomized tri-
als with either inhaled32 or intravenous adminis-
tration33,34 of beta2 agonists.35 The results show
either no effect (inhaled) or increased (intra-
venous route) risk of death (aggregate risk ratio,
1.14; 95% CI, 0.91–1.42) and a significant
increase in the risk of cardiac arrhythmias (risk
ratio, 1.8; 95% CI, 1.24–2.62) and time on
mechanical ventilation (both routes of adminis-
tration; mean difference, 2.2 days; 95% CI, 0.71–
3.68). The quality of evidence was downgraded
due to imprecision and inconsistency.
Recommendation 4: Neuromuscular
blocking agents (NMBAs) (Appendix A;
Table S4, Fig S4)
We suggest that neuromuscular blocking agents
(NMBAs) may be used in the early stages of
severe ARDS (weak recommendation, moderate
quality of evidence). This recommendation is
based on findings from three randomized tri-
als36–38 and a systematic review and meta-analy-
sis by Alhazzani et al.39 No individual trial
demonstrated significant benefit from the use of
NMBAs, but aggregate data from all trials
demonstrated a significant effect on the risk of
death (risk ratio, 0.70; 95% CI, 0.55–0.89).
However, trial sequential analysis indicates that
the findings in the systematic review may be
subject to random errors (a spurious finding due
to repetitive testing), as the total number of
included patients of all trials was small com-
pared to what would have been necessary in a
randomized trial with sufficient power
(Appendix A; Fig S4i I-II). Thus, the quality of
evidence was downgraded due to imprecision.
Recommendation 5: Inhaled nitric oxide
(iNO) (Appendix A; Table S5, Fig S5)
A. We recommend against the routine use of iNO
in adults with ARDS (strong recommendation,
moderate quality of evidence). This does not pre-
clude the use of iNO in patients with an underly-
ing condition or co-existing disease in which
iNO is indicated (e.g. severe pulmonary hyper-
tension). Our recommendation is based on two
*Following completion of our review, Norita et al. published a system-
atic review on the use of corticosteroids in ARDS (Norita H et al.
Intern Med 2015; 54: 1473–9). The findings of this review do not alter
our recommendation. Data will be included in a later iteration of our
guideline.
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recent systematic reviews40,41 that found no effect
of iNO on the risk of death in adults with ARDS
– regardless of their oxygenation status – and
importantly, an increased risk of kidney injury, a
very severe complication in ARDS patients (risk
ratio, 1.8; 95% CI, 1.17–2.79). The quality of evi-
dence was downgraded due to imprecision.
B. The above results notwithstanding, we sug-
gest that iNO may be used as a rescue measure
to temporarily increase oxygenation in patients
with catastrophic hypoxemia and imminent risk
of death (weak recommendation, moderate qual-
ity of evidence).
Recommendation 6: Prostanoids
(Appendix A; Table S6, Fig S6)
We recommend against routine use of Epopros-
tenol inhalation in adults with ARDS (strong
recommendation, very low quality of evidence).
This does not preclude the use of Epoprostenol
in patients with an underlying condition or co-
existing disease in which it is indicated (e.g.
severe pulmonary hypertension). Our recom-
mendation is based on a recent Cochrane sys-
tematic review comprising one low risk of bias
RCT (n = 14 children) that found no statistically
significant effect of Epoprostenol on 28-day
mortality.42 None of the other outcomes of inter-
est were reported. The quality of evidence was
downgraded for imprecision and indirectness.
Recommendation 7: Statins (Appendix A;
Table S7, Fig S7)
We recommend against the routine use of statins
in adults with ARDS (strong recommendation,
low quality of evidence). This does not preclude
the use of statins in patients with an underlying
condition or co-existing disease in which statins
are indicated (e.g. coronary heart disease). Our
recommendation is based on two recently pub-
lished randomized trials that showed heteroge-
neous and largely imprecise effects of either
simvastatin or rosuvastatin on mortality and
other patient-important outcomes.43,44
Recommendation 8: Other drugs
In adults with ARDS, we issue a strong recom-
mendation against the routine use of any drug
regimen that has not already been covered in
the above paragraphs. Our strong recommenda-
tion is based on an a priori very low quality of
evidence, i.e. the absence of relevant and well-
performed randomized trials. Enthusiasm for the
apparent logic of some therapeutic options
should be tempered by the absence of support-
ive data from empirical evidence and unknown
potential for harm.
Discussion
In adopting the GRADE system for guideline
development, the SSAI has emphasized that
guidelines should inform readers about clini-
cally relevant issues based on current best evi-
dence and avoid advice based solely on expert
opinion.
We were able to use existing high-quality sys-
tematic reviews of randomized trials to answer
most clinical questions. However, in assessing
the evidence base for fluid therapy and statins,
no relevant meta-analyses or systematic reviews
were found. We, therefore, conducted meta-ana-
lyses ourselves, based on systematic literature
searches (see Appendix A). Also, we amended
the dataset from an existing meta-analysis of
iNO to include data published by Adhikari
et al.41
Several interventions included in our analysis
highlight the importance of weighing benefits
vs. harms by the clinician: Fluid restriction may
shorten time on mechanical ventilation, but may
also increase the risk of cognitive dysfunction
following critical illness. Also, in the FACTT
trial, allowance was made for less restrictive
fluid management in patients with shock, mak-
ing the overall results difficult to interpret19 (we
have avoided developing guidance based on
subgroup analyses only). Similarly, corticos-
teroids may possibly improve weaning from
mechanical ventilation at the price of a higher
death rate in the follow-up period.29 On the
other hand, data generally do not indicate a
higher risk of infection in ARDS patients man-
aged with steroids.
Beta-2-agonists have been widely used to
manage mechanically ventilated patients with
airway secretions and loosely defined airway
‘obstruction’ in mechanically ventilation. Trial
data lend no support to such therapy. The
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increased risk of arrhythmias, time on mechan-
ical ventilation, and death seen in trials
should remind us to reserve the use of these
drugs for patients with true obstructive
airways disease.
NMBAs are widely used by anaesthesiologists
to facilitate endotracheal intubation and surgery.
Recent interest for their use in patients with
severe respiratory failure results from trials per-
formed by the French intensive care net-
work.36,38,45 These trials and the meta-analysis
used in this guideline highlight several impor-
tant methodological issues that we carefully
considered before issuing a weak recommenda-
tion for use of NMBA in ARDS. The imprecise
effect estimates and the fact that all trials have
been performed in one intensive care network
results in what we consider to be moderate
quality of evidence for a reduction in death and
no apparent increased risk of adverse events.39
The results also receive some support from a
large observational study in US hospitals.46 In
mechanically ventilated adults, receipt of a
NMBA was associated with a reduced risk of
in-hospital mortality (risk ratio, 0.88; 95% CI,
0.80–0.96).
Inhaled nitric oxide improves oxygenation, but
it has no demonstrable effect on risk of death,
and it significantly increases the risk of kidney
injury. The finding that nitric oxide significantly
improved oxygenation (p/f ratio; mean differ-
ence, 20.67 mmHg; 95% CI, 11.39–29.95)† exem-
plifies how misleading surrogate findings may be
in the light of demonstrable harm to patients.
However, in patients with life-threatening
hypoxemia, the use of NMBAs and nitric oxide
may provide transitory relief. We believe that
most individuals would prefer risk of kidney
injury if iNO could raise oxygen to a level that,
for example, facilitated transportation to an
ECMO centre. Rescue therapies for the most sev-
ere cases of ARDS will be the subject of a sepa-
rate future SSAI clinical practice guideline. In
general, existing data indicate that nitric oxide no
longer has a role in routine management of adults
with ARDS and should be curtailed.
Prostanoids has no proven beneficial effect
and has only been assessed in 14 children. Con-
sequently, prostanoids should not be used out-
side the context of randomized clinical trials.
Similarly, statins and other drugs directed at the
inflammatory cascade have yet to be proven
beneficial.
Why develop Nordic guidelines for intensive
care medicine? Across the Nordic societies, there
is considerable professional, cultural, and eco-
nomic homogeneity. This is important because
there are many shared values, preferences, and
resource considerations throughout our societies.
These are important elements in the GRADE sys-
tem. Intensive care medicine, and particularly
mechanical ventilation, has a longstanding tradi-
tion in Nordic anaesthesiology, and much of the
early pioneering work was done by anaesthetists
in the Nordic countries.47–49 It is, therefore, only
natural that SSAI develops guidelines and stan-
dards that emphasize the role of anaesthesiology
in intensive care medicine.
The guideline process serves to inform us that,
despite advances, many areas of our practice
remain characterized by a paucity of high-qual-
ity evidence. Ideally, guideline developers work
in concert with trialists to make informed
choices when allocating resources for costly
investigations. Close collaboration with research
groups, including the Scandinavian Critical Care
Trials Group (SCCTG), is therefore essential for
further progress.
Limitations
A limitation of this work is that we have relied
heavily on the use of the McMaster Plus data-
base in selecting reviews for our work. We can-
not exclude the possibility that an independent
approach might have revealed additional data
that were not included in our work. We do,
however, find it highly unlikely that we could
have improved on the quality of the algorithms
used by McMaster.
Also, we restricted our recommendations to
those that can be deduced from randomized tri-
als only. The re-definition of hypoxemic respira-
tory failure into mild, moderate, and severe
ARDS3 simplifies trial selection. Our analyses
still suffer from significant trial heterogeneity
(i.e. variability in published studies with
respect to the severity of illness in patients
included in each trial, and also by the heteroge-
neous nature of any underlying disease and the†Corresponds to 2.76 kPa (1.52–3.99).
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timing of inclusion of patients following devel-
opment of ARDS). Examples include corticos-
teroid trials that utilize a variety of dose
regimens and duration of therapy (Appendix A;
Table S2; Fig S2). This leaves the clinician who
cares for ARDS patients and who applies our
guideline, with the choice between a conserva-
tive approach based on available evidence from
randomized trials, and careful use of new treat-
ment options and physiological targets. We can-
not exclude that available observational studies
may provide valuable evidence to inform some
of our recommendations. Indeed observational
studies may result in moderate- to high-quality
evidence according to the GRADE system
although such cases are few and far between.50
Further limitations of this guideline result
from lack of stakeholder involvement, that is,
patient groups and relatives, as well as regula-
tory bodies and hospital owners (i.e. public rep-
resentatives). Also, we did not include intensive
care nurses who care for patients with ARDS.
Although the rationale for many treatment
options have been that the intervention has
been shown to improve physiological parame-
ters (e.g. oxygenation), the history of critical
care research has often shown that such a strat-
egy may be faulty. In a recently published anal-
ysis of multicentre critical care interventions,
eight critical care interventions actually
increased mortality.51 Also, we have learned
that it is not obvious which part of our patho-
physiological insight will provide therapeutic
strategies that benefit patients; the practice of
gentle ventilation derives from the ‘baby lung’
concept that was developed from experimental
and clinical studies of lung mechanics in
ARDS.52 In clinical practice, gentle ventilation
will often challenge us to accept blood gases
that are far from ‘normal’, yet the benefit to
patients has been clearly demonstrated.53 Con-
versely, inhaled nitric oxide may significantly
improve oxygenation, particularly in the acute
stage of ARDS,40 but no clinical benefit has yet
been demonstrated in randomized trials and
there are severe side effects. Whether due to
study design or harms that outweigh benefit,
the available literature does not allow strong
recommendations for any of the assessed ARDS
interventions. We believe that it is correct to
avoid giving recommendations based on physio-
logical data only and hope that gaps in our list
of recommendations may stimulate future high-
quality Scandinavian multicentre trials.
Conclusion
This clinical practice guideline, as well as the
recently published guideline on mechanical ven-
tilation in adults with ARDS,54 represent a body
of recommendations developed in accordance
with the principles for trustworthy guidelines
developed by the international guideline commu-
nity and the GRADE working group. We invite
readers of this guideline to carefully review the
evidence base for our recommendations, adapt
recommendations when necessary, and use the
recommendations in a balanced manner also
informed by their own judgment to guide clinical
practice to the benefit of their patients.
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